CancerDrs

Lymphoma clinical trials in Kansas

19 actively recruiting lymphoma trials at 26 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Kansas:
  • Cancer Center of Kansas - Chanute — Chanute, Kansas
  • Cancer Center of Kansas - Dodge City — Dodge City, Kansas
  • Cancer Center of Kansas - El Dorado — El Dorado, Kansas
  • HaysMed — Hays, Kansas
  • Cancer Center of Kansas-Independence — Independence, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Kansas:
  • Wesley Medical Center — Wichita, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Kansas:
  • Cotton O'Neil Cancer Center ( Site 0108) — Topeka, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Kansas:
  • The University of Kansas Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Kansas:
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07069699
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 unt…

Sponsor: Eli Lilly and Company
NCT ID: NCT07101328
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cel…

Sponsor: Marker Therapeutics, Inc.
NCT ID: NCT05798897
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in …

Sponsor: University of Kansas Medical Center
NCT ID: NCT03533816
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19